XML 32 R8.htm IDEA: XBRL DOCUMENT v3.22.4
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Cash Flows From Operating Activities:      
Net loss $ (184,780) $ (163,929) $ (47,695)
Adjustments to reconcile net loss to net cash provided by operating activities:      
Depreciation and amortization 3,853 3,534 3,498
Share-based compensation expense 160,743 142,660 28,211
Non-cash operating leases expense 2,281 2,115 2,029
Amortization of premium on marketable securities 277 1,162 543
Gain on sale of equity method investment (17,889) 0 0
Impairment of other financial instruments 11,616 0 0
Other 649 3,110 1,929
Changes in operating assets and liabilities:      
Accounts receivable (2,577) (4,940) (4,485)
Settlements receivable (6,762) 1,601 (2,961)
Network incentives receivable (12,262) (10,377) (9,400)
Prepaid expenses and other assets (8,621) (7,742) (2,481)
Accounts payable 254 190 (839)
Revenue share payable 21,015 42,988 48,442
Accrued expenses and other liabilities 22,257 49,372 34,997
Operating lease liabilities (3,020) (2,772) (1,515)
Net cash (used in) provided by operating activities (12,966) 56,972 50,273
Cash flows from investing activities:      
Purchases of property and equipment (2,319) (2,743) (2,375)
Purchase of patents (1,600) 0 0
Purchases of marketable securities (70,495) (455,266) (216,200)
Sales of marketable securities 0 0 71,981
Maturities of marketable securities 77,400 148,888 89,032
Purchase of equity method investment and purchase option 0 (20,000) 0
Sale of equity method investment 25,732 0 0
Net cash provided by (used in) investing activities 28,718 (329,121) (57,562)
Cash flows from financing activities:      
Proceeds from initial public offering, net of underwriters’ discounts and commissions 0 1,319,809 0
Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs 0 0 166,942
Proceeds from exercise of stock options, including early exercised stock options, net of repurchase of early exercised unvested options 9,249 4,539 3,144
Proceeds from exercise of warrants 0 60 0
Proceeds from shares issued in connection with employee stock purchase plan 4,762 3,201 0
Taxes paid related to net share settlement of restricted stock units (15,362) (23,552) 0
Repurchase of common stock (78,136) 0 0
Payment of deferred offering costs 0 (4,760) (2,708)
Net cash (used in) provided by financing activities (79,487) 1,299,297 167,378
(Decrease) Increase in cash, cash equivalents, and restricted cash (63,735) 1,027,148 160,089
Cash, cash equivalents, and restricted cash - Beginning of period 1,255,381 228,233 68,144
Cash, cash equivalents, and restricted cash - End of period $ 1,191,646 $ 1,255,381 $ 228,233